(Q34419108)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

title

Do current therapeutic anti-Aβ antibodies for Alzheimer's disease engage the target? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

0 references

1 reference

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Adam P Gunn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Catriona A. McLean

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Michael W Parker

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

author name string

Andrew D Watt

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Gabriela A N Crespi

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Russell A Down

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Keyla A Perez

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Victor L Villemagne

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Kevin J Barnham

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

Luke A Miles

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

publication date

7 May 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

published in

Acta Neuropathologica

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

volume

127

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

17 March 2020

page(s)

803-810

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24803227%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s00401-014-1290-2

17 March 2020

exact match

0 references

cites work

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Molecular mechanisms for Alzheimer's disease: implications for neuroimaging and therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Alzheimer's disease: strategies for disease modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Sting of Alzheimer's failures offset by upcoming prevention trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

An effector-reduced anti-β-amyloid (Aβ) antibody with unique aβ binding properties promotes neuroprotection and glial engulfment of Aβ.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Oligomers, fact or artefact? SDS-PAGE induces dimerization of β-amyloid in human brain samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Blood-borne amyloid-beta dimer correlates with clinical markers of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Robust prediction of the MASCOT score for an improved quality assessment in mass spectrometric proteomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Probability-based protein identification by searching sequence databases using mass spectrometry data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Pharmacokinetic analysis of the blood-brain barrier transport of 125I-amyloid beta protein 40 in wild-type and Alzheimer's disease transgenic mice (APP,PS1) and its implications for amyloid plaque formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Resolving controversies on the path to Alzheimer's therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Testing the right target and right drug at the right stage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

The epitope space of the human proteome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Probing the basis of antibody reactivity with a panel of constrained peptide libraries displayed by filamentous phage

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2

Antibody multispecificity mediated by conformational diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-014-1290-2